Key positives include a focused, science‑driven strategy in immuno‑oncology; a lead asset designed specifically to overcome safety issues that have derailed competitors; and a broader platform that touches multiple immune mechanisms and even oncology diagnostics. Management has shown some willingness to rein in overhead costs, and historically the company has been able to raise capital and unlock liquidity through financings and asset transactions.

Major risks center on the lack of any revenue, deep and widening losses, a sharply weakened balance sheet with negative equity and elevated debt, and ongoing cash burn that depends on external funding. Scientific risk is high: all core value is tied to unproven programs, especially IBA101, in a very competitive and failure‑prone field. The unconventional move into cryptocurrency and blockchain creates additional strategic uncertainty, raising questions about focus, regulatory complexity, and potential distraction from the core biotech mission.

The forward picture is that of a high‑risk, high‑uncertainty biotech trying to convert promising preclinical science into clinical proof and, eventually, commercial relevance, all while operating under significant financial constraints. Progress on regulatory filings and early‑phase trials for IBA101 and the GCC programs, along with clarity on how (or whether) the crypto initiative fits into a coherent long‑term plan, will be critical determinants of future prospects. Until there is either convincing clinical data or a clearer path to sustainable funding, the company’s trajectory will remain highly speculative and sensitive to both scientific outcomes and capital‑market conditions.